PMID- 34373376
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20220315
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Print)
IS  - 0918-2918 (Linking)
VI  - 61
IP  - 3
DP  - 2022 Feb 1
TI  - Intravenous Immunoglobulin in the Treatment of Adalimumab-associated Optic 
      Neuritis.
PG  - 429-432
LID - 10.2169/internalmedicine.7599-21 [doi]
AB  - Optic neuritis (ON) is a rare complication of tumor necrosis factor (TNF)-alpha 
      inhibitors. The autoantibody serostatus, treatment, and outcome of TNF-alpha 
      inhibitor-associated ON remain unclear. We herein report a 50-year-old woman with 
      ON following adalimumab therapy. The patient presented with decreasing visual 
      acuity of the right eye, quickly diminishing to light perception. 
      Anti-aquaporin-4 (anti-AQP4) and anti-myelin oligodendrocyte glycoprotein 
      antibodies were negative. Adalimumab was discontinued, and intravenous 
      methylprednisolone and intravenous immunoglobulin (IVIg) were administered. 
      However, her visual acuity improved only up to counting fingers. IVIg may be 
      ineffective depending on the pretreatment severity.
FAU - Uchio, Naohiro
AU  - Uchio N
AD  - Department of Neurology, Mitsui Memorial Hospital, Japan.
FAU - Yashita, Daiki
AU  - Yashita D
AD  - Department of Neurology, Mitsui Memorial Hospital, Japan.
FAU - Hao, Akihito
AU  - Hao A
AD  - Department of Neurology, Mitsui Memorial Hospital, Japan.
FAU - Takahashi, Toshiyuki
AU  - Takahashi T
AD  - Department of Neurology, Tohoku University Graduate School of Medicine, Japan.
AD  - Department of Neurology, National Hospital Organization Yonezawa National 
      Hospital, Japan.
FAU - Matsumoto, Hideyuki
AU  - Matsumoto H
AD  - Department of Neurology, Mitsui Memorial Hospital, Japan.
LA  - eng
PT  - Case Reports
PT  - Journal Article
DEP - 20210806
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Aquaporin 4)
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab/adverse effects
MH  - Aquaporin 4
MH  - Autoantibodies
MH  - Female
MH  - Humans
MH  - *Immunoglobulins, Intravenous/therapeutic use
MH  - Middle Aged
MH  - Myelin-Oligodendrocyte Glycoprotein
MH  - *Optic Neuritis/chemically induced/diagnosis/drug therapy
PMC - PMC8866781
OTO - NOTNLM
OT  - adalimumab
OT  - aquaporin-4
OT  - intravenous immunoglobulin
OT  - myelin oligodendrocyte glycoprotein
OT  - optic neuritis
OT  - tumor necrosis factor-alpha
COIS- The authors state that they have no Conflict of Interest (COI).
EDAT- 2021/08/11 06:00
MHDA- 2022/02/05 06:00
PMCR- 2022/02/01
CRDT- 2021/08/10 05:52
PHST- 2021/08/11 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2021/08/10 05:52 [entrez]
PHST- 2022/02/01 00:00 [pmc-release]
AID - 10.2169/internalmedicine.7599-21 [doi]
PST - ppublish
SO  - Intern Med. 2022 Feb 1;61(3):429-432. doi: 10.2169/internalmedicine.7599-21. Epub 
      2021 Aug 6.